

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/142231 A8

(43) International Publication Date
15 July 2021 (15.07.2021)

(51) International Patent Classification:

A61K 33/24 (2019.01) *A61K 33/245* (2019.01)
A61K 33/241 (2019.01) *A61K 33/30* (2006.01)
A61K 33/244 (2019.01)

98021 (US). **HU, Meiduo**; 10584 Bathurst Street, Maple, Ontario, L94 4Y4 (CA). **VALLIANT, John, Fitzmaurice**; 15 Holkham Avenue, Ancaster, Ontario L9K 1N8 (CA). **PATEL, Sonal**; 270 Longwood Road South, Hamilton, Ontario L8P 0A6 (CA).

(21) International Application Number:

PCT/US2021/012656

(22) International Filing Date:

08 January 2021 (08.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/959,879 10 January 2020 (10.01.2020) US
63/037,520 10 June 2020 (10.06.2020) US

(71) Applicant: **FUSION PHARMACEUTICALS INC.**
[CA/CA]; 270 Longwood Road South, Hamilton, Ontario L8P 0A6 (CA).

(72) Inventors: **BURAK, Eric, Steven**; 40 James Street, Cambridge, Ontario N1S 1C5 (CA). **METCALF, Julie**; 100 Gothic Avenue, Toronto, Ontario M6P 2V9 (CA). **GRINSHEIN, Natalie**; 3630 212th Pl. SE, Bothwell, WA

(74) Agent: **BIEKER, Kristina** et al.; c/o Patent Administrator, Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: SUSTAINED IMMUNOTHERAPY




FIG. 2H

(57) Abstract: Methods of inducing CD8+ T cell infiltration into a tumor in a patient in need thereof comprising administering a radioimmunoconjugate that is capable of binding a target expressed by at least some cells in a tumor. In some embodiments, the CD8+ T cell population that infiltrates into the tumor persists in the patient and may therefore act to prevent metastases from forming and/or reduce the likelihood of recurrences.

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

28 July 2022 (28.07.2022)

(15) Information about Correction:

see Notice of 28 July 2022 (28.07.2022)